What's Happening?
Arima Genomics, a cancer diagnostics company, is set to present new data at the Association for Molecular Pathology (AMP) 2026 Europe Congress, demonstrating that its Hi-C sequencing technology outperforms high-coverage whole genome sequencing (WGS) in detecting
lymphoma rearrangements. The study involved 25 FFPE lymphoma specimens and showed that Hi-C sequencing identified clinically relevant structural variants that WGS missed, particularly those involving key lymphoma-associated genes. This technology offers a more comprehensive view of genome structure, enabling the detection of diagnostic, prognostic, and therapeutic biomarkers that are critical for accurate lymphoma diagnosis and treatment.
Why It's Important?
The findings from Arima Genomics underscore the potential of Hi-C sequencing to revolutionize cancer diagnostics by providing a more detailed and accurate analysis of genetic rearrangements. This is particularly important for lymphoma, where precise detection of genetic alterations is crucial for effective treatment planning. By surpassing the capabilities of traditional methods like FISH and WGS, Hi-C sequencing could lead to improved patient outcomes and more personalized treatment strategies. The ability to detect a broader range of genetic alterations also supports the development of targeted therapies, which are increasingly important in the fight against cancer.
What's Next?
Following the presentation of these findings, Arima Genomics is likely to continue expanding the clinical application of Hi-C sequencing, potentially leading to its adoption as a standard diagnostic tool in oncology. The company may also explore partnerships with healthcare providers and research institutions to further validate and refine the technology. As the demand for precision medicine grows, Hi-C sequencing could play a pivotal role in advancing cancer diagnostics and treatment, offering new hope for patients with complex genetic profiles.
